ClinicalTrials.gg
CompletedNCT06071546Updated Aug 13, 2024

Clinical Investigation of a New Version of MAIA Microperimeter on Healthy Subjects and Patients With Retinal Pathology

An interventional study of MAIA in Healthy Eyes and Retinal Diseases, sponsored by Centervue SpA. Completed at 1 site in Switzerland. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-13.

Sponsored by Centervue SpA · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
68
Allocation
Not applicable
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Retinal Diseases with a site in Switzerland — 1 open to participants now, 1 under way, none of them phase 3. Retinal Diseases · Switzerland.

Started
2023
with 1 other
No phase
4 of 11
1 open now
Registered
11th of 11
by date
Lead sponsor
1 of 11
Centervue SpA

Among the 11 studies in Retinal Diseases with a site in Switzerland, this one is one of 2 that started in 2023, is one of 4 with no phase, and was the 11th registered.

Retinal Diseases

333 studies on the registry are indexed under Retinal Diseases; 59 are open to participants now.

Browse Retinal Diseases studies →

Open to participants now

1 of the 11 studies in Retinal Diseases with a site in Switzerland is open now. Recruiting first, the newest first:

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 44 Retinal Diseases studies recruiting now, 30 (68%) set no upper age limit and 4 (9%) stop at 75 or younger; 16 take children under 18; 19 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Retinal Diseases with a site in Switzerland, or all of them as a file.
02

Study summary

The purpose of this pre-market, monocentric cross-sectional study is to evaluate the clinical usefulness of a new version of the MAIA device (MAIA) through an agreement with the established version of the MAIA microperimeter (MAIA 2013 EDITION). Moreover, the study aims to evaluate MAIA test-retest repeatability in comparison with MAIA 2013 EDITION and to evaluate MAIA safety and adverse events. These purposes will be achieved by collecting data of healthy subjects and patients with retinal pathology. All participants will undergo repeated microperimetric examinations with both devices during one single visit.

03

Conditions studied

  • Healthy Eyes
  • Retinal Diseases

Browse trials for

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Healthy Subjects

Inclusion Criteria:

  • Age: 18-90 years old;
  • BCVA ≥ 0.8 Decimal;
  • Equivalent spherical refraction between -12D and +6D; astigmatism within 2D;
  • IOP ≤ 21 mmHg;
  • Clinically normal appearance of the optic nerve head (examined with Spectralis OCT);
  • Clinically normal appearance of the macula (examined with Spectralis OCT);
  • No ocular pathologies, trauma, surgeries;
  • Absence of pathologies that can affect visual field;
  • No use of drugs inferfering with the correct execution of perimetry;

Exclusion Criteria:

  • Glaucoma or glaucoma suspect diagnosis;
  • IOP ≥ 22 mmHg;
  • Presence or history of disc hemorrhage;
  • Presence of amblyopia;
  • Nystagmus or poor fixation;
  • Previous laser or any ocular surgery, including uncomplicated cataract surgery performed within 6 months before enrollment;
  • Any active infection of anterior or posterior segments;
  • Subjects with significant ocular media opacities;
  • Evidence of diabetic retinopathy, diabetic macular edema, or other retinal disease;
  • Use of any drug that can interfere with the correct execution of microperimetry or that would produce visual field loss;
  • Unable to tolerate ophthalmic imaging;
  • Claustrophobia;
  • Inability to provide .

Patients with retinal pathology

Inclusion Criteria:

  • Age: 18-90 years old;
  • BCVA ≥ 0.1 Decimal;
  • Equivalent spherical refraction between -12D and +6D; astigmatism within 2D;
  • Diagnosis of any type of retinal disease by investigator based on fundoscopy and Spectralis OCT for which microperimetry is indicated;

Exclusion Criteria:

  • Any ocular surgery, with the exception of uncomplicated cataract surgery performed at least 6 months before enrollment;
  • Subjects unable to tolerate ophthalmic imaging;
  • Nystagmus;
  • Subjects with significant ocular media opacities;
  • Use of any drug that can interfere with the correct execution of microperimetry or that would produce visual field loss;
  • Claustrophobia;
  • Inability to provide informed consent;
  • Vulnerable subjects according to the investigator's judgement.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
68 participants (actual)

Study arms

  • Experimental
    Main arm

    * one microperimetric examination with MAIA, one microperimetric examination with MAIA 2013 EDITION for agreement evaluation; * one additional microperimetric examination with MAIA and one additional microperimetric examination with MAIA 2013 EDITION for repetability evaluation.

    Device: MAIA

Interventions

  • DeviceMAIA

    MAIA is a visual field testing device combining visual field tests, fixation loss correction by a real-time retinal tracker and confocal TrueColor fundus imaging (P/N AHMACME001)

06

What researchers measure

Primary outcomes

  1. To evaluate the limits of agreement between MAIA and MAIA 2013 EDITION for threshold sensitivity values.

    Agreement will be quantified by using the method proposed by Bland and Altman \[1,2,3\], estimating the 95%-Limits of Agreement (LoA) of the difference of threshold sensitivity values. The acceptance criteria for agreement between MAIA and MAIA 2013 EDITION is that MAIA's 95% LoA limits are within MAIA 2013 EDITION repeatability limits. 1. Bland JM, Altman DG (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1(8476):307-10. 2. Bland JM, Altman DG (1999) Measuring agreement in method comparison studies. Statistical Methods in Medical Research 8:135-160 3. Bland JM, Altman DG (2007), Agreement Between Methods of Measurement with Multiple Observations Per Individual, Journal of Biopharmaceutical Statistics 17:571-82

    Time frame: 1 day

Secondary outcomes

  1. To assess the repeatability limits of retinal threshold sensitivity values obtained with MAIA

    The acceptance criteria is that the 95% LoA limits for MAIA are at least as narrow as MAIA 2013 EDITION repeatability limits.

    Time frame: 1 day

  2. To assess the avoidance of Serious Adverse Device Effects with MAIA

    During the clinical investigation, adverse events will be documented, investigated and reported according to the provisions of applicable reporting guidelines, following their criteria and timelines

    Time frame: through study completion (expected duration: 3 months)

07

Study locations

1 site
  • Universitätsspital Basel, Augenklinik
    Basel, CH-4031, Switzerland
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in Jul 2024, 8 months.

Of 42 interventional studies with no phase under Retinal Diseases, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 66. This study's 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2023
First posted
Oct 6, 2023
StartActual
Oct 17, 2023
Primary completionActual
Jul 12, 2024
CompletionActual
Jul 12, 2024
Last update
Aug 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06071546
Lead sponsor
Centervue SpA
Responsible party
Sponsor
First posted
Oct 6, 2023
Start date
Oct 17, 2023
Primary completion
Jul 12, 2024
Completion
Jul 12, 2024
Last update
Aug 13, 2024

Study contacts

Maximilian Pfau, PD Dr. med.
principal investigator · Universitätsspital Basel, Augenklinik

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion